Sandoz Limited have informed the MHRA of errors in the dosing table in the Summary of Product Characteristics (SmPC) for Co-amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension.
Important: This alert is gathered automatically for information only. Always refer to the original source and follow your practice’s own clinical governance procedures.
About this source
Alerts and Recalls for Drugs and Medical Devices - General Practice